Here we show that GP64-LV is suitable for in vivo gene transfer since it is resistant to complement-mediated inactivation, allows highly efficient targeting of LSEC, and thus can be exploited to express FVIII in its physiologic site of production, achieving correction of hemophilia A in mice. The gene discussed is F8; the disease is hemophilia A.